全文获取类型
收费全文 | 129930篇 |
免费 | 10312篇 |
国内免费 | 3613篇 |
专业分类
耳鼻咽喉 | 1016篇 |
儿科学 | 3133篇 |
妇产科学 | 1934篇 |
基础医学 | 7190篇 |
口腔科学 | 2880篇 |
临床医学 | 16910篇 |
内科学 | 19326篇 |
皮肤病学 | 2317篇 |
神经病学 | 6614篇 |
特种医学 | 4091篇 |
外国民族医学 | 39篇 |
外科学 | 13148篇 |
综合类 | 18626篇 |
现状与发展 | 24篇 |
一般理论 | 4篇 |
预防医学 | 5785篇 |
眼科学 | 2046篇 |
药学 | 10362篇 |
83篇 | |
中国医学 | 11019篇 |
肿瘤学 | 17308篇 |
出版年
2024年 | 202篇 |
2023年 | 2471篇 |
2022年 | 3347篇 |
2021年 | 5815篇 |
2020年 | 5542篇 |
2019年 | 5011篇 |
2018年 | 4745篇 |
2017年 | 5176篇 |
2016年 | 5434篇 |
2015年 | 5190篇 |
2014年 | 9426篇 |
2013年 | 11893篇 |
2012年 | 7642篇 |
2011年 | 8178篇 |
2010年 | 6712篇 |
2009年 | 6208篇 |
2008年 | 6033篇 |
2007年 | 6450篇 |
2006年 | 5748篇 |
2005年 | 5146篇 |
2004年 | 4170篇 |
2003年 | 3750篇 |
2002年 | 3043篇 |
2001年 | 2708篇 |
2000年 | 2248篇 |
1999年 | 1750篇 |
1998年 | 1449篇 |
1997年 | 1224篇 |
1996年 | 934篇 |
1995年 | 914篇 |
1994年 | 731篇 |
1993年 | 554篇 |
1992年 | 491篇 |
1991年 | 452篇 |
1990年 | 384篇 |
1989年 | 339篇 |
1988年 | 325篇 |
1987年 | 284篇 |
1986年 | 222篇 |
1985年 | 263篇 |
1984年 | 229篇 |
1983年 | 173篇 |
1982年 | 170篇 |
1981年 | 167篇 |
1980年 | 131篇 |
1979年 | 127篇 |
1978年 | 66篇 |
1977年 | 46篇 |
1976年 | 50篇 |
1975年 | 34篇 |
排序方式: 共有10000条查询结果,搜索用时 36 毫秒
21.
22.
Adjuvant irradiation is the standard treatment after breast conservative surgery. Normofractionated regimen with an overall treatment time of 5 to 6 weeks is often considered as a limiting factor for irradiation compliance. In order to answer this issue, moderate and more recently extreme hypofractionated protocols appeared. We report here oncological outcomes and toxicity of hypofractionated breast irradiation. After defining the frame of moderate and extreme hypofractionated breast irradiations based on overall treatment time, patient selection criteria were listed. According to their levels of proof, the results of moderate and extreme hypofractionated breast irradiation were analysed. Overall treatment time for moderate hypofractionated breast irradiation ranged from 3 to 4 weeks, while for extreme hypofractionated breast irradiation, it was less than 1 week. For moderate hypofractionated breast irradiation, whole breast irradiation was currently performed with or without lymph node irradiation. Moderate hypofractionated breast irradiation has proven to be as safe and as efficient as normofractionated breast irradiation with level IA evidence. For extreme hypofractionated breast irradiation, phase III randomized trials confirmed that accelerated partial breast irradiation was non-inferior in terms of local control compared to normofractionated whole breast irradiation (with external beam radiation therapy and multicatheter brachytherapy), with similar acute and late toxicity. While the use of intraoperative breast irradiation remains under debate, new very accelerated partial breast irradiation (overall treatment time not exceeding 2 days) protocols emerged with encouraging results. Accelerated partial breast irradiation is warranted for extreme hypofractionated breast irradiation and is indicated for low-risk breast cancers. Moderate and extreme hypofractionated breast irradiation regimens are validated and can be routinely proposed according to patient selection criteria. 相似文献
23.
24.
《Obstetrics, Gynaecology and Reproductive Medicine》2020,30(6):175-183
Menopause is generally experienced as a biopsychosocial process involving physiological changes, and influenced by a wide range of psychological, social and cultural factors. The loss of ovarian oestrogen production may cause debilitating symptoms, including hot flushes, night sweats, sleep disturbance, vaginal dryness, dyspareunia, bladder dysfunction, loss of libido, and mood changes. Experience of the menopause transition varies widely between individuals, depending on the age of onset, personal health and wellbeing, social context, environment and culture.Hormone Replacement Therapy (HRT) remains the most effective treatment for the management of vasomotor symptoms and vaginal dryness, but has no proven role in the treatment of chronic diseases of ageing. Treatment should be individualized, and for most healthy women aged 50–59 years the risks of HRT are low. An understanding of the pathophysiology of menopausal symptoms and the risks and benefits of both hormonal and non-hormonal treatments assists in the individual management of patients. 相似文献
25.
26.
27.
28.
29.
《Journal of thoracic oncology》2020,15(4):618-627
IntroductionPembrolizumab has shown clinical benefit in patients with previously treated recurrent or metastatic SCLC in the phase 1b multicohort study KEYNOTE-028 (NCT02054806) and the phase 2 multicohort study KEYNOTE-158 (NCT02628067). We present a pooled analysis of patients from KEYNOTE-028 and KEYNOTE-158 who had received two or more lines of previous therapy for SCLC.MethodsEligible patients were aged 18 years and above, had histologically or cytologically confirmed incurable recurrent or metastatic SCLC, had an Eastern Cooperative Oncology Group performance status of 1 and below, and had received two or more lines of previous therapy. Patients in KEYNOTE-028 were required to have a programmed death ligand 1 (PD-L1)–positive tumor. Patients received pembrolizumab (10 mg/kg every 2 weeks in KEYNOTE-028 or 200 mg every 3 weeks in KEYNOTE-158) for up to 2 years. The primary end point was objective response rate per Response Evaluation Criteria in Solid Tumors version 1.1, which is presented here per independent review.ResultsEighty-three patients who had received two or more lines of previous therapy (KEYNOTE-028, n = 19; KEYNOTE-158, n = 64) were included. Median follow-up duration was 7.7 (range, 0.5–48.7) months. Objective response rate was 19.3% (95% confidence interval: 11.4–29.4); two patients had complete response (one with a PD-L1–positive tumor), and 14 patients had partial response (13 with PD-L1–positive tumors). The median duration of response was not reached (range, 4.1‒35.8+ mo; plus sign indicates ongoing response); 61% of responders had responses lasting 18 months or longer. Fifty-one patients (61.4%) experienced any-grade treatment-related adverse events; eight patients (9.6%) had grade 3 or higher events.ConclusionsPembrolizumab exhibited durable antitumor activity in a subset of patients with recurrent or metastatic SCLC who had undergone two or more previous lines of therapy, regardless of PD-L1 expression. Pembrolizumab was well tolerated. 相似文献